Trials / Conditions / HR+ Breast Cancer
HR+ Breast Cancer
6 registered clinical trials studyying HR+ Breast Cancer — 5 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Not Yet Recruiting | SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breas NCT07307287 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Not Yet Recruiting | Study Assessing the Efficacy and Safety of cANnabidiol Oral Solution for Joint Pain of Adjuvant enDOcrine theR NCT06787118 | Gustave Roussy, Cancer Campus, Grand Paris | Phase 3 |
| Not Yet Recruiting | SC-101 in Subjects With Advanced NECTIN4-Amplified Cancers NCT07080619 | Tianjin ConjuStar Biologics Co., Ltd. | Phase 2 |
| Recruiting | A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors NCT07029399 | NiKang Therapeutics, Inc. | Phase 1 |
| Recruiting | Anlotinib-based Combination Therapy in Patients with Hormone Receptor-positive（HR+） Metastatic Breast Cancer(M NCT06734533 | Hunan Cancer Hospital | — |
| Terminated | (VELA) Study of BLU-222 in Advanced Solid Tumors NCT05252416 | Blueprint Medicines Corporation | Phase 1 |